Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bubendorf

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
ANX7, a candidate tumor suppressor gene for prostate cancerM Srivastava, L Bubendorf, V Srikantan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†A Zer, M-J Ahn, F Barlesi, et al.
The Journal of Biological Chemistry|November 24, 1999
A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivoS K Lee, S L Anzick, J E Choi, et al.
ESMO Open|July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14D König, S Savic Prince, S Hayoz, et al.
The New England Journal of Medicine|February 24, 2001
Gene-expression profiles in hereditary breast cancerI Hedenfalk, D Duggan, Y Chen, et al.
The Journal of Pathology|July 6, 2001
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological gradeA Nocito, L Bubendorf, E M Tinner, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
ESMO Open|January 5, 2021
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near futureP Hofman, M Ilié, E Chamorey, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
ANX7, a candidate tumor suppressor gene for prostate cancerM Srivastava, L Bubendorf, V Srikantan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†A Zer, M-J Ahn, F Barlesi, et al.
The Journal of Biological Chemistry|November 24, 1999
A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivoS K Lee, S L Anzick, J E Choi, et al.
ESMO Open|July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14D König, S Savic Prince, S Hayoz, et al.
The New England Journal of Medicine|February 24, 2001
Gene-expression profiles in hereditary breast cancerI Hedenfalk, D Duggan, Y Chen, et al.
The Journal of Pathology|July 6, 2001
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological gradeA Nocito, L Bubendorf, E M Tinner, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
ESMO Open|January 5, 2021
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near futureP Hofman, M Ilié, E Chamorey, et al.
Pageof 9